In­smed shares soar as PhI­II lung dis­ease study proves pos­i­tive, point­ing to quick FDA pitch

Shares of In­smed $IN­SM rock­et­ed up 133% in pre­mar­ket trad­ing on Tues­day af­ter the biotech re­port­ed that its Phase III study had hit the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.